Pipeline

Robust Pipeline with Multiple T-Cell Immunotherapy Product Candidates in Clinical Development

tab-cel® (tabelecleucel)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
EBV+ PTLD following HCT

EBV+ PTLD following SOT

1st line EBV+ PTLD

Other EBV-associated cancers

Nasopharyngeal carcinoma (NPC)

Multiple Sclerosis (MS)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Autologous ATA190: Progressive MS

Allogeneic ATA188: Progressive MS and RRMS

Next Generation CAR T Pipeline
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA2321: AML

ATA2431: B-cell malignancies

ATA3219: B-cell malignancies

Solid tumor CAR T programs

Autoimmune disease CAR T program

Infectious disease CAR T program

Other Programs
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA230: Refractory CMV Infection and Disease Post HCT/SOT

ATA520: Hematologic malignancies

ATA621: JCV PML and BKVAN

ATA368: HPV associated cancers